CTA311 is an investigational ‘ready-at-point of care’ allogeneic anti-CD19 CAR-T cell therapy designed for B-cell mediated disease. The product candidate incorporates T-cell receptor (TCR) and HLA ...

Tesla has long been the poster child for electric-vehicle innovation, and despite recurring controversies the brand has ...

The concept of marketing has transitioned. Advertisements have moved away from being passive announcements to being designs people can participate in. Brands are now designing illustrations that their ...

Arima Genomics, Inc ., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced new data to be presented at the ...

In an ambitious push to restore public spaces, Patna officials have initiated an extensive anti-encroachment campaign, raking in Rs 59,800 in penaltie ...

First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework ...

The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...

● Conference: ESMO Immuno-Oncology (ESMO-IO) 2025 Annual Congress ● Title: CAPTN-3 unique design demonstrated by 2 novel platform compounds ● Presenter: Dr. Hadas Reuveni ● Presentation Number: FPN# ...

A 3-foot-long sculpture inspired by Journey’s Dream Mobile airship – with Figment and Dreamfinder aboard – is estimated by ...

If your work involves biologics manufacturing — from early-stage development to scale-up and quality assurance — this Xchange offers more than just insights: it delivers access to a community of ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent ...